Along with Rachel Sachs, Jacob S. Sherkow, and Nicholson Price, Lisa Larrimore Ouellette has been publishing a regular series on COVID-19 innovation law and policy. This page has a compilation of posts so far, in reverse chronological order. You can also download these posts through April 2021 as a single collection here.

  1. What does ending the COVID-19 pandemic mean from a legal perspective? (6/8/22)
  2. How do we encourage innovation on “long COVID”? (3/3/22)
  3. What are the challenges in developing information around mixing-and-matching COVID-19 vaccines and therapies? (1/21/22)
  4. How does pregnancy factor into COVID-19 innovation? (12/6/21)
  5. Molnupiravir may become the first COVID-19 pill. What took so long? (10/5/21)
  6. How would the proposed American Pandemic Preparedness Plan help address underinvestment in pandemic-related innovation? (9/27/21)
  7. How does the CDC’s Advisory Committee on Immunization Practices impact innovation and access to COVID-19 vaccines? (8/27/21)
  8. What’s happening with proposals for a WTO waiver of COVID-related IP? (7/30/21)
  9. Why do differences in clinical trial design make it hard to compare COVID-19 vaccines? (6/30/21)
  10. What’s the difference between vaccine approval (BLA) and authorization (EUA)? (6/3/21)
  11. What can policymakers learn from the UK’s RECOVERY trial to improve clinical research for COVID-19 and beyond? (5/3/21)
  12. How can Congress create infrastructure for the next pandemic? (4/9/21)
  13. How are COVID-19 vaccine developers and regulators responding to variants? (3/25/21)
  14. Are patents the cause of—or solution to—COVID-19 vaccine innovation problems? (No!) (3/4/21)
  15. How can policymakers overcome the hurdles to scaling up antibody manufacturing? (2/18/21)
  16. Why aren’t therapeutic antibodies being used more to treat COVID-19? (1/29/21)
  17. What can policymakers learn from the disastrously slow COVID-19 vaccine rollout? (1/12/21)
  18. How can policymakers encourage COVID-19 vaccine trials for children? (12/18/20)
  19. What administrative actions might we expect on COVID-19 in President-elect Biden’s administration? (11/30/20)
  20. What role is AI playing in the COVID-19 pandemic? (11/21/20)
  21. What did we learn from last week’s FDA vaccine advisory committee meeting? (10/30/20)
  22. What is—and should be—the military’s role in COVID-19 research? (10/12/20)
  23. How are COVID-19 vaccine manufacturers aiming to encourage trust in the FDA’s approval process? (10/2/20)
  24. What are the innovation challenges to scaling vaccine manufacturing? (9/10/20)
  25. Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing? (8/25/20)
  26. Multi-Agency Funding for COVID-19 Vaccine Development (8/19/20)
  27. How is the NIH seeking to encourage investment in diagnostic testing for COVID-19? (8/13/20)
  28. Are COVID-19 vaccine advance purchases a form of vaccine nationalism, an effective spur to innovation, or something in between? (8/5/20)
  29. How should policymakers use “pull” mechanisms to improve COVID-19 innovation incentives? (7/30/20)
  30. How should policymakers incentivize and regulate convalescent serum therapy for COVID-19? (7/22/20)
  31. How will the FDA’s new COVID-19 vaccine guidance affect development efforts? (7/10/20)
  32. Racial disparities in healthcare innovation in the time of COVID-19 (7/2/20)
  33. How can health regulators maintain public trust when facing scientific uncertainty? (6/24/20)
  34. How can the government improve access to COVID-19 preventatives and treatments for low-income Americans? (6/18/20)
  35. Structural Racism and COVID-19 (6/11/20)
  36. How can policymakers encourage the expansion of at-home diagnostic testing for COVID-19? (6/3/20)
  37. Nonexcludable Innovations and COVID-19 (5/27/20)
  38. Remdesivir Part II: Allocating Access (5/19/20)
  39. Remdesivir Part I: Incentivizing Antiviral Innovation (5/12/20)
  40. How is regulatory policy influencing the development and marketing of antibody testing for COVID-19? (5/4/20)
  41. How does the law impact the use of 3D printing to address COVID-19 production shortages? (4/27/20)
  42. Regulatory Responses to N95 Respirator Shortages (4/21/20)
  43. How can innovation and regulatory policy accomplish robust COVID-19 testing? (4/15/20)
  44. How can the US address coronavirus drug shortages? (4/7/20)
  45. What does it mean that Oracle is partnering with the Trump administration to study unproven COVID-19 drugs? (3/3/20)
Other Written Description COVID-19 posts:
Other commentary on COVID-19 innovation law and policy by Lisa Larrimore Ouellette:
  1. Q&A on Waiving COVID-19 Vaccine Patents (5/4/21, for Stanford's Legal Aggregate)
  2. Valuing the Vaccine (9/21/20 video preview of talk to Harvard Law Petrie-Flom Center with Daniel Hemel)
  3. Innovation Policy Pluralism and COVID-19 (7/23/20 talk in Iowa Innovation, Business & Law Center Summer Speaker Series)
  4. Innovation Policy and the Market for Vaccines (5/18/20 article in Journal of Law and the Biosciences, with Qiwei Claire Xue)
  5. Innovation Policy and Covid-19 (4/9/20 talk to Stanford Center for Law & the Biosciences, with Daniel Hemel)
  6. Pharmaceutical Profits and Public Health Are Not Incompatible (4/8/20 op-ed in The New York Times, with Daniel Hemel)
  7. Want a Coronavirus Vaccine, Fast? Here's a Solution (3/4/20 op-ed in TIME, with Daniel Hemel)

No comments:

Post a Comment